Impact of IFNL4 genetic variants on sustained virologic response and viremia in hepatitis C virus genotype 3 patients by Pedergnana, V, Irving, W, Barnes, E, McLauchlan, J, Spencer, C

Host genetic factors associated with hepatocellular carcinoma in patients with hepatitis C virus infection: A systematic review by Walker, A, Peacock, C, Pedergnana, V, STOP-HCV Consortium, Irving, W

Interferon lambda 4 variant rs12979860 is not associated with RAV NS5A Y93H in hepatitis C virus genotype 3a by Pedergnana, V, Smith, D, Klenerman, P, Barnes, E, Spencer, C, Ansari, M

Inference of Host–Pathogen Interaction Matrices from Genome-Wide Polymorphism Data by Märkle, H, John, S, Metzger, L, STOP-HCV Consortium, Ansari, MA, Pedergnana, V, Tellier, A

Inference of Host–Pathogen Interaction Matrices from Genome-Wide Polymorphism Data by Märkle, H, John, S, Metzger, L, STOP-HCV Consortium, Ansari, MA, Pedergnana, V, Tellier, A

Impact of IFNL4 genotype on interferon-stimulated gene expression during daa therapy for Hepatitis C by Ramamurthy, N, Marchi, E, Ansari, M, Pedergnana, V, MClean, A, Hudson, E, STOP-HCV Consortium, Bowden, R, Spencer, C, Barnes, E, Klenerman, P

Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure by Smith, DA, Fernandez-Antunez, C, Magri, A, Bowden, R, Chaturvedi, N, Fellay, J, McLauchlan, J, Foster, GR, Irving, WL, Barnes, E, Simmonds, P, Pedergnana, V, Ramirez, S, Bukh, J, Ansari, MA

Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus by Sy, A, McCabe, L, Hudson, E, Ansari, AM, Pedergnana, V, Lin, S-K, Santana, S, Fiorino, M, Ala, A, Stone, B, Smith, M, Nelson, M, Barclay, ST, McPherson, S, Ryder, SD, Collier, J, Barnes, E, Walker, AS, Pett, SL, Cooke, G

Evidence of CD4+ T cell-mediated immune pressure on the Hepatitis C virus genome by Lucas, M, Deshpande, P, James, I, Rauch, A, Pfafferott, K, Gaylard, E, Merani, S, Plauzolles, A, Lucas, A, McDonnell, W, Kalams, S, Pilkinton, M, Chastain, C, Barnett, L, Prosser, A, Mallal, S, Fitzmaurice, K, Drummer, H, Ansari, M, Pedergnana, V, Barnes, E, John, M, Kelleher, D, Klenerman, P, Gaudieri, S

In vivo negative regulation of SARS-CoV-2 receptor, ACE2, by interferons and its genetic control by Ansari, A, Marchi, E, Ramamurthy, N, Aschenbrenner, D, Morgan, S, Hackstein, C-P, Lin, S-K, Bowden, R, Sharma, E, Pedergnana, V, Venkateswaran, S, Kugathasan, S, Mo, A, Gibson, G, Cooke, G, McLauchlan, J, Baillie, JK, Teichmann, S, Mentzer, A, Knight, J, Todd, J, Hinks, T, Barnes, E, Klenerman, P, Uhlig, H

Genome-to-genome analysis highlights the effect of the human innate and adaptive immune systems on the hepatitis C virus by Ansari, M, Pedergnana, V, Ip, C, Magri, A, Von Delft, A, Bonsall, D, Chaturvedi, N, Bartha, I, Smith, D, Nicholson, G, McVean, G, Trebes, A, Piazza, P, Fellay, J, Cooke, G, Foster, G, STOP-HCV Consortium, Hudson, E, McLauchlan, J, Simmonds, P, Bowden, R, Klenerman, P, Barnes, E, Spencer, C

Interferon lambda 4 impacts the genetic diversity of hepatitis C virus by Ansari, M, Aranday-Cortes, E, Ip, C, Da Silva Filipe, A, Lau, S, Bamford, C, Bonsall, D, Trebes, A, Piazza, P, Sreenu, V, Cowton, V, Stop-Hcv Consortium, Ball, J, Barnes, E, Burgess, G, Cooke, G, Dillon, J, Foster, G, Gore, C, Guha, N, Halford, R, Holmes, C, Hudson, E, Hutchinson, S, Irving, W, Khakoo, S, Klenerman, P, Martin, N, Mbisa, T, McKeating, J, McLauchlan, J, Miners, A, Murray, A, Shaw, P, Simmonds, P, Smith, S, Spencer, C, Thomson, E, Troke, P, Vickerman, P, Zitzmann, N, Hudson, E, Bowden, R, Patel, A, Foster, G, Irving, W, Agarwal, K, Thomson, E, Simmonds, P, Klenerman, P, Holmes, C, Barnes, E, Spencer, C, McLauchlan, J, Pedergnana, V